JP2020519621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519621A5 JP2020519621A5 JP2019561977A JP2019561977A JP2020519621A5 JP 2020519621 A5 JP2020519621 A5 JP 2020519621A5 JP 2019561977 A JP2019561977 A JP 2019561977A JP 2019561977 A JP2019561977 A JP 2019561977A JP 2020519621 A5 JP2020519621 A5 JP 2020519621A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- medicament according
- drug
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 40
- 201000011510 cancer Diseases 0.000 claims 33
- 239000003814 drug Substances 0.000 claims 29
- 229940079593 drug Drugs 0.000 claims 12
- 201000009030 Carcinoma Diseases 0.000 claims 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 9
- 208000032818 Microsatellite Instability Diseases 0.000 claims 8
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims 8
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 7
- 230000007547 defect Effects 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 230000033607 mismatch repair Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 230000033616 DNA repair Effects 0.000 claims 3
- 206010064571 Gene mutation Diseases 0.000 claims 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 229940125644 antibody drug Drugs 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 3
- 229950011068 niraparib Drugs 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- -1 JPI 289 Chemical compound 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000003101 oviduct Anatomy 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims 1
- NAORJNSNFJUGHU-UHFFFAOYSA-N 1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one Chemical compound C1CSCC2=C1NC=NC2=O NAORJNSNFJUGHU-UHFFFAOYSA-N 0.000 claims 1
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims 1
- HRYKZAKEAVZGJD-UHFFFAOYSA-N 2-methyl-3,5,7,8-tetrahydro-4h-thiopyrano[4,3-d]pyrimidin-4-one Chemical compound C1CSCC2=C1N=C(C)NC2=O HRYKZAKEAVZGJD-UHFFFAOYSA-N 0.000 claims 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 claims 1
- HYNBNUYQTQIHJK-UHFFFAOYSA-N 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CC(OC)CCN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F HYNBNUYQTQIHJK-UHFFFAOYSA-N 0.000 claims 1
- XJGXCBHXFWBOTN-UHFFFAOYSA-N 4-[[4-fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1CN2N=C(C(F)(F)F)N=C2CN1C(=O)C1=CC(CC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F XJGXCBHXFWBOTN-UHFFFAOYSA-N 0.000 claims 1
- QNQFPYADHVFRKQ-UHFFFAOYSA-N 4-[[4-fluoro-3-[5-methyl-3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl]phenyl]methyl]-2h-phthalazin-1-one Chemical compound C1=CC=C2C(CC=3C=C(C(=CC=3)F)C(=O)N3CC(N4C(=NN=C4C3)C(F)(F)F)C)=NNC(=O)C2=C1 QNQFPYADHVFRKQ-UHFFFAOYSA-N 0.000 claims 1
- GRPXLKXGJAGYSD-UHFFFAOYSA-N 6-[4-[(5-oxo-2,3,4,6-tetrahydro-1H-benzo[h][1,6]naphthyridin-8-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile Chemical compound O=C1C=2CCCNC=2C2=C(N1)C=C(C=C2)CN1CCN(CC1)C1=NC=C(C#N)C=C1 GRPXLKXGJAGYSD-UHFFFAOYSA-N 0.000 claims 1
- JLFSBHQQXIAQEC-UHFFFAOYSA-N 9x5a2qia7c Chemical compound C1=CC(C(=O)NN2)=C3C2=NC(CN2CC4=CC=CC=C4C2)=NC3=C1 JLFSBHQQXIAQEC-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- BWVHYDYUKQEFHG-UHFFFAOYSA-N cep-8983 Chemical compound COC1=CC=CC2=C1C1=C3C(=O)NC(=O)C3=C3CCCC3=C1N2 BWVHYDYUKQEFHG-UHFFFAOYSA-N 0.000 claims 1
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- HAVFFEMDLROBGI-UHFFFAOYSA-N m8926c7ilx Chemical compound C1CC(O)CCN1CC1=CC=C(OC=2C3=C(C(NN=C33)=O)C=CC=2)C3=C1 HAVFFEMDLROBGI-UHFFFAOYSA-N 0.000 claims 1
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 claims 1
- 229950004707 rucaparib Drugs 0.000 claims 1
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023067482A JP7717749B2 (ja) | 2017-05-09 | 2023-04-17 | 癌を治療するための併用療法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503879P | 2017-05-09 | 2017-05-09 | |
| US62/503,879 | 2017-05-09 | ||
| US201762508359P | 2017-05-18 | 2017-05-18 | |
| US62/508,359 | 2017-05-18 | ||
| US201762556255P | 2017-09-08 | 2017-09-08 | |
| US62/556,255 | 2017-09-08 | ||
| US201862634789P | 2018-02-23 | 2018-02-23 | |
| US62/634,789 | 2018-02-23 | ||
| US201862646332P | 2018-03-21 | 2018-03-21 | |
| US62/646,332 | 2018-03-21 | ||
| US201862648327P | 2018-03-26 | 2018-03-26 | |
| US62/648,327 | 2018-03-26 | ||
| PCT/US2018/031876 WO2018208968A1 (en) | 2017-05-09 | 2018-05-09 | Combination therapies for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067482A Division JP7717749B2 (ja) | 2017-05-09 | 2023-04-17 | 癌を治療するための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519621A JP2020519621A (ja) | 2020-07-02 |
| JP2020519621A5 true JP2020519621A5 (https=) | 2021-06-10 |
Family
ID=64105496
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561977A Pending JP2020519621A (ja) | 2017-05-09 | 2018-05-09 | 癌を治療するための併用療法 |
| JP2023067482A Active JP7717749B2 (ja) | 2017-05-09 | 2023-04-17 | 癌を治療するための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023067482A Active JP7717749B2 (ja) | 2017-05-09 | 2023-04-17 | 癌を治療するための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12156872B2 (https=) |
| EP (1) | EP3621592A4 (https=) |
| JP (2) | JP2020519621A (https=) |
| KR (1) | KR20200018436A (https=) |
| CN (1) | CN110831580A (https=) |
| AU (3) | AU2018264992A1 (https=) |
| BR (1) | BR112019023591A2 (https=) |
| CA (1) | CA3063201A1 (https=) |
| IL (1) | IL270511B2 (https=) |
| MA (1) | MA48637A (https=) |
| MX (1) | MX2019013373A (https=) |
| TW (2) | TW202444417A (https=) |
| WO (1) | WO2018208968A1 (https=) |
| ZA (1) | ZA201907395B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| TW201938165A (zh) * | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN113116881B (zh) * | 2019-12-31 | 2025-03-07 | 甫康（上海）健康科技有限责任公司 | 一种用于治疗肿瘤的药物组合及其应用 |
| EP4190819A4 (en) * | 2021-03-12 | 2024-08-14 | Akeso Biopharma, Inc. | PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| WO2025128263A1 (en) * | 2023-12-15 | 2025-06-19 | Pharmaessentia Corporation | Anti-pd-1 monoclonal antibody and methods of preparation thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059571T3 (es) | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| CA1329771C (en) | 1988-09-01 | 1994-05-24 | Shoji Kishimoto | Angiogenesis inhibitory agent |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| US9707302B2 (en) * | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP2217244A4 (en) | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| WO2009087474A2 (en) | 2008-01-08 | 2009-07-16 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CN102307475A (zh) | 2009-02-04 | 2012-01-04 | 彼帕科学公司 | 用与生长因子抑制剂组合的parp抑制剂治疗肺癌 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011153383A1 (en) * | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
| EP3012329B1 (en) | 2010-06-18 | 2017-10-25 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| US9738915B2 (en) | 2012-12-07 | 2017-08-22 | Merck Sharp & Dohme Corp. | Biocatalytic transamination process |
| US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2015086473A1 (en) * | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) * | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| WO2015116868A2 (en) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| PL3102605T3 (pl) | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| WO2015184145A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| US20160160294A1 (en) | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX2017015937A (es) * | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
| JP6980980B2 (ja) * | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| JP7042739B2 (ja) * | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| SG11201803462PA (en) | 2015-10-26 | 2018-05-30 | Medivation Tech Llc | Treatment of small cell lung cancer with a parp inhibitor |
| US20210322415A1 (en) | 2016-02-15 | 2021-10-21 | Astrazeneca Ab | Methods comprising fixed intermittent dosing of cediranib |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110087730B (zh) | 2016-09-27 | 2023-03-28 | 百济神州(苏州)生物科技有限公司 | 使用包含parp抑制剂的组合产品治疗癌症 |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| WO2018129553A1 (en) * | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| KR20190130625A (ko) | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) * | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210106574A1 (en) | 2017-12-27 | 2021-04-15 | Tesaro, Inc. | Methods of Treating Cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
| US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-05-09 TW TW113103416A patent/TW202444417A/zh unknown
- 2018-05-09 TW TW107115829A patent/TWI879716B/zh active
- 2018-05-09 CA CA3063201A patent/CA3063201A1/en active Pending
- 2018-05-09 KR KR1020197036164A patent/KR20200018436A/ko active Pending
- 2018-05-09 AU AU2018264992A patent/AU2018264992A1/en not_active Abandoned
- 2018-05-09 BR BR112019023591-4A patent/BR112019023591A2/pt active Search and Examination
- 2018-05-09 CN CN201880044978.4A patent/CN110831580A/zh active Pending
- 2018-05-09 MA MA048637A patent/MA48637A/fr unknown
- 2018-05-09 IL IL270511A patent/IL270511B2/en unknown
- 2018-05-09 JP JP2019561977A patent/JP2020519621A/ja active Pending
- 2018-05-09 EP EP18797986.9A patent/EP3621592A4/en not_active Withdrawn
- 2018-05-09 MX MX2019013373A patent/MX2019013373A/es unknown
- 2018-05-09 US US16/612,363 patent/US12156872B2/en active Active
- 2018-05-09 WO PCT/US2018/031876 patent/WO2018208968A1/en not_active Ceased
-
2019
- 2019-11-07 ZA ZA2019/07395A patent/ZA201907395B/en unknown
-
2021
- 2021-08-18 AU AU2021218080A patent/AU2021218080B2/en active Active
-
2023
- 2023-04-17 JP JP2023067482A patent/JP7717749B2/ja active Active
- 2023-11-29 AU AU2023274126A patent/AU2023274126A1/en not_active Abandoned
- 2023-12-15 US US18/541,600 patent/US20240226082A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519621A5 (https=) | ||
| JP2020503364A5 (https=) | ||
| JP2020536066A5 (https=) | ||
| McCormack | Nintedanib: first global approval | |
| KR101258426B1 (ko) | 세포 증식과 관련된 질환 치료용 배합물 | |
| CN111093706B (zh) | Parp抑制剂用于治疗化疗耐药的卵巢癌或乳腺癌的用途 | |
| Das et al. | Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024) | |
| JP2020536869A5 (https=) | ||
| Jing et al. | Aurora kinase inhibitors: a patent review (2014-2020) | |
| Meiss et al. | Vismodegib | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| JP2018527383A5 (https=) | ||
| Li et al. | Combination of anti-EGFR and anti-VEGF drugs for the treatment of previously treated metastatic colorectal cancer: a case report and literature review | |
| Wei et al. | Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment | |
| Gryziak et al. | Milestones in the treatment of hepatocellular carcinoma: A systematic review. | |
| Personeni et al. | Targeted agents for second-line treatment of advanced hepatocellular carcinoma | |
| TW202535405A (zh) | 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑 | |
| EP3883561A1 (en) | Pharmaceutical methods | |
| Schvartsman et al. | An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients | |
| JP2025517908A5 (https=) | ||
| CN112543646B (zh) | 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途 | |
| Zhang et al. | Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive‐stage small‐cell lung cancer patients (DURABLE study) | |
| Landi et al. | Ceritinib for the treatment of non-small cell lung cancer | |
| WO2023051606A1 (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| Cao et al. | Poly (ADP-Ribosyl) polymerase 1 inhibitors: A patent review |